BMJ2d
EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis: 2023 update
Introduction Hip and knee osteoarthritis (OA) are increasingly common with a significant impact on individuals and society. Non-pharmacological treatments are considered essential to reduce pain and ...
BMJ3d
Psoriatic arthritis therapy: NSAIDs and traditional DMARDs
Non-steroidal anti-inflammatory drugs (NSAIDs) and traditional disease modifying antirheumatic drugs (DMARDs) are widely used in the treatment of psoriatic arthritis (PsA), but this is based more upon ...
BMJ3d
Burden and trajectory of multimorbidity in rheumatoid arthritis: a matched cohort study from 2006 to 2015
Correspondence to Dr Bryant R England, Division of Rheumatology & Immunology, University of Nebraska Medical Center, Omaha, NE 68198, USA; bryant.england{at}unmc.edu Objectives To compare the onset ...
BMJ3d
Guidelines for musculoskeletal ultrasound in rheumatology
aDepartment of Rheumatology and Clinical Immunology, Charité University Hospital, Humboldt University, Berlin, Germany, bDepartment of Rheumatology and Physical Medicine, University Hospital, Zurich, ...
BMJ5d
EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update
Background Since the publication of the EULAR recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in 2016, several randomised clinical trials ...
BMJ5d
Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment
Objectives Fatigue is a frequent symptom in rheumatoid arthritis (RA) and has high impact on quality of life. We explored associations between disease activity and fatigue in patients with early RA ...
BMJ10d
Psoriatic arthritis: epidemiology, clinical features, course, and outcome
1 University of Toronto, Toronto Western Research Institute, Psoriatic Arthritis Program, University Health Network, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, ...
BMJ12d
Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis
Objective This observational cohort study investigated the impact of biological (b) disease-modifying antirheumatic drugs (DMARDs) on the outcomes of serious infections (SIs) in patients with ...
BMJ16d
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial
7 CIRI/Rheumatology & Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Fraunhofer Cluster of Excellence for Immune-Mediated Disease (CIMD), Goethe University, Frankfurt, ...
BMJ16d
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
Correspondence to Dr Dimitrios T Boumpas, Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, "Attikon" University Hospital, Joint Academic Rheumatology Program, National ...
BMJ17d
Effects of bariatric surgery on gout incidence in the Swedish Obese Subjects study: a non-randomised, prospective, controlled intervention trial
Objectives To assess the long-term effect of bariatric surgery on the incidence of gout and hyperuricaemia in participants of the Swedish Obese Subjects (SOS) study. Methods This report includes 1982 ...
BMJ20d
Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases
A substantial and persuasive body of data now exists that supports the view that integrin alpha V beta 3 plays a critical part in activated macrophage dependent inflammation, osteoclast development, ...